Navigation Links
Generic Growth Strategies
Date:8/15/2013

DUBLIN, August 15, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/fcrtlb/generic_growth) has announced the addition of the "Generic Growth Strategies - Market Driven by Impending Patent Cliff, Declining R&D Productivity and Government Initiatives to Reduce Healthcare Costs" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

Market Driven by Impending Patent Cliff, Declining R&D Productivity and Government Initiatives to Reduce Healthcare Costs

Generic Giants Strategize to Exploit Massive Patent Cliff Potential

Huge rewards and strong competition are prompting generic drug manufacturers to closely examine the best way to maximize market share as the industry patent cliff approaches its peak, states a new report from business intelligence analysts.

According to the firm's latest report, the revenues of drugs subject to patent expiration between 2013 and 2020 are valued at over US$100 billion, offering producers of generics and biosimilars a fantastic opportunity to substantially bolster their own sales.

However, while the next few years hold great promise for these companies, fierce competition exists not only from rival generics manufacturers, but also from major pharmaceutical players looking to maintain market dominance with Authorized Generics' (AG). In response, generics firms are re-evaluating their approach to the market.

Research states that companies such as Hospira are reaching out to new locales in order to build a global presence, while targeting governments looking to bring down healthcare costs. Exploiting pharmaceutically underdeveloped economies may allow generics firms to launch products first, challenging the intellectual property of proprietary pharmaceutical majors.

Generics producers also hope to capitalize on expiring patents by manufacturing complex generics that are difficult to reproduce. These super generics have high barriers to entry, a greater price than most other generics and incur greater Research and Development (R&D) costs; however, there is significant potential for super generics within specific therapeutic areas, such as cancer and conditions involving the central nervous system.

Research expects demand for high-quality generics to increase in the future, as key drugs lose patent protection and governments are offered opportunities to provide vital treatments at significantly reduced costs.

Key Topics Covered:

1.1 List of Tables
1.2 List of Figures

2 Generic Growth Strategies - Introduction

3 Generic Growth Strategies - Market Overview

4 Generic Growth Strategies - Regulatory Landscape

5 Generic Growth Strategies - Major Strategies

6 Generic Growth Strategies - Competitive Landscape

7 Generic Growth Strategies - Conclusion

8 Generic Growth Strategies - Appendix

Companies Mentioned

- Teva Pharmaceutical Industries Limited
- Sandoz
- Mylan
- Watson
- Actavis
- Hospira
- Sanofi
- Daiichi Sankyo
- Aspen
- STADA

For more information visit http://www.researchandmarkets.com/research/fcrtlb/generic_growth

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices


'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Launches Generic Version of Zyprexa® Tablets
2. Coloplast Wins Patent Infringement Verdict Against Generic Medical Devices, Inc.
3. Mylan Launches Generic Lipitor® in Five European Countries
4. Mylan Launches Generic Version of Plavix® Tablets
5. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
6. Prodigy Generics and eVenus Announce the Launch of Oncology Injectable Irinotecan.
7. Mylan Launches Generic Version of Viramune® Tablets
8. Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy
9. Sihuans First-to-market Generic Drug Roxatidine Passes On-site Inspection for Drug Registration Conducted by the Chinese State Food and Drug Administration
10. Mylan Announces Settlement Agreement in Litigation Relating to its Generic Xopenex®
11. Mylan Launches Generic Version of Lipitor®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/19/2017)...  Mako Medical Laboratories partnered with Secretary Strickland, the ... Fund (MFA) to bring 140 soldiers back home to ... families one last time before being deployed. Mako Medical ... logistics needed for these soldiers. "Mako Medical Laboratories is ... We just wish we could bring them all home," ...
(Date:7/13/2017)...  Centurion Medical Products, a leader in medical product innovation and ... removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part of a ... pain while preventing unneeded emergency department admission due to severe fecal ...
(Date:7/11/2017)... , July 11, 2017 Zymo Research Corp., also known ... that can quantify biological aging in a precise manner using the myDNAge ... Steve Horvath , a professor of human genetics and biostatistics at the ... School of Public Health , Zymo Research,s proprietary DNAge ™ technology ... ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... Thomas Jefferson ... Witness , was awarded a $300,000 grant from The Pew Center for Arts ... with ambiguity and the recognition of one’s own limits among health professions students. ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... $5,000 grant from the C. R. Bard Foundation, Inc. to support ... Hills , a service available through the nonprofit home care agency. Using evidence-based ...
(Date:7/21/2017)... ... 21, 2017 , ... In the first prospective ACL reconstruction ... Outcome Network (MOON) demonstrated that patients could perform sports-related functions and maintain a ... over time. The study, presented today at the American Orthopaedic Society for ...
(Date:7/20/2017)... MA (PRWEB) , ... July 20, 2017 , ... ... form of blood and bone marrow cancer that progresses rapidly without treatment. Newly ... recommended to reduce the chance of reoccurrence and relapse. With such a ...
(Date:7/20/2017)... ATLANTA, Ga. (PRWEB) , ... July 20, 2017 , ... ... and equal access to medicine for everyone affected by diabetes, is teaming up with ... the five-day global event kicks off on July 24th. , “Team Type 1’s ...
Breaking Medicine News(10 mins):